Immunoassay biomarker test menu market seen reaching $0.95 billion by 2030

The Business Research Company says the immunoassay biomarker test menu expansion market will grow from $0.53 billion in 2025 to $0.6 billion in 2026, then reach $0.95 billion by 2030. The report points to chronic disease monitoring, precision medicine, AI-driven diagnostics and multiplex testing as the main growth drivers.

Why it matters: - Expanded biomarker test menus let laboratories detect more disease signals from immunoassay techniques. - That can improve early diagnosis, disease monitoring and treatment decisions. - The market growth reflects rising demand for more comprehensive diagnostic tools as chronic disease rates climb.

What happened: - The Business Research Company published a 2026 market report on the global immunoassay biomarker test menu expansion market. - The market is projected to rise from $0.53 billion in 2025 to $0.6 billion in 2026. - The report forecasts the market will reach $0.95 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the next several years.

The details: - The market is expected to grow at a 12.2% CAGR from 2025 to 2026. - The report projects a 12.4% CAGR through 2030. - Growth in the historical period is tied to higher rates of chronic and infectious diseases. - Wider use of immunoassay diagnostics in clinical laboratories is supporting expansion. - Stronger hospital diagnostic infrastructure is adding capacity. - Greater awareness of early disease detection and preventive care is also lifting demand. - Government funding for diagnostic research and laboratory modernization has supported growth. - Future growth is expected to come from precision medicine and personalized biomarker profiling. - AI and automation are increasingly being integrated into diagnostic workflows. - Multiplex and high-throughput testing platforms are expanding adoption. - Companion diagnostics in drug development are contributing to demand. - Early detection programs for cancer and chronic illnesses are expected to add more demand. - The report defines immunoassay biomarker test menu expansion as broadening the range of biomarkers detectable through immunoassay techniques. - New assays and improved existing tests can increase diagnostic accuracy and disease monitoring. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report includes a free sample and the full market report through the company’s sample request page and the full report.

Between the lines: - The report frames the market as part of a broader shift toward earlier, more personalized and higher-throughput diagnostics. - North America's current lead suggests established diagnostic infrastructure, while Asia-Pacific's growth outlook points to faster adoption and capacity buildout. - The disease burden cited in the report supports the idea that demand is being pulled by ongoing monitoring needs, not just one-time testing.

What's next: - The market’s near-term path will likely depend on adoption of multiplex platforms, automation and companion diagnostics. - Continued investment in laboratory modernization and early detection programs could widen test menus further. - The report suggests the strongest growth opportunity will come from products that combine broader biomarker coverage with faster workflow integration.

The bottom line: - Expanded immunoassay biomarker testing is moving from a niche capability to a growth market shaped by chronic disease, precision medicine and diagnostics automation.